RxY, a division of healthcare research specialist P\S\L Group, has made four appointments in research teams and four in sales, including Molly Feda as Managing Director in Europe. The business helps pharma companies track the real reasons why Rx choices are made when physicians are prescribing.
RxY promises to uncover the 'true why / why not' behind physician treatment choices, combining rich qual data with large sample quant to fill the gaps it says are left by quant-only research.
The appointments cover the globe: Isabel Crane becomes a Research Manager in the US and Roberta Falzari in Europe, while Jorge Villamil and Zeena Morar take the title of Research Assistant, in Mexico and South Africa respectively.
Feda (pictured) brings fourteen years' experience from medical and pharma sector commercial leadership to the role of Managing Director, while Mike Webber also joins in Europe, as Sales Director. In the US Ryan Wilson joins as Sales Director and Nicole Heinrich as Senior Sales Director.
'The remarkable growth and adoption of our service over the past four years has been truly gratifying' says Global MD Paul O'Shaughnessy. 'This success, coupled with the unwavering support of our clients, has enabled us to invest in expanding our team. These strategic new hires will enhance RxY's capacity to assist our clients in gaining deeper insights into the factors driving therapy selection'.
The division is on the web at www.rxyhc.com ,
All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.
Register (free) for Daily Research News
REGISTER FOR NEWS EMAILS
To receive (free) news headlines by email, please register online